Heather Cook

Heather Cook

Auto-generated profile, based on publicly available information

Heather Cook

University of Exeter

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2024 in Health Technology Assessment
Verified
Journal Article
Open access
PDF file
AWAlexandra Wright-Hughes
Alexandra Wright-Hughes
AFAlexander C Ford
Alexander C Ford
SASarah L Alderson
Sarah L Alderson
POPei Loo Ow
Pei Loo Ow
MRMatthew J Ridd
Matthew J Ridd
AFAmanda J Farrin
Amanda J Farrin
Background: Irritable bowel syndrome, characterised by abdominal pain and a change in stool form or frequency, is most often managed in primary care. When first-line therapies are ineffective, National Institute for Health and Care Excellence guidelines suggest considering low-dose tricyclic antidepressants as second-line treatment, but their effectiveness in primary care is unknown and they are infrequently prescribed by general practitioners. Objective: To evaluate the clinical and cost-effectiveness of low-dose titrated amitriptyline as a second-line treatment for irritable bowel syndrome in primary care. Design: A pragmatic, randomised, multicentre, two-arm, double-blind, placebo-controlled trial. A nested, qualitative study explored participant and general practitioner experiences of treatments and trial participation, and implications for wider use of amitriptyline for irritable bowel syndrome in primary care. Participants, clinicians, investigators and analysts were masked to allocation. Setting: Fifty-five general practices in three regions in England (Wessex, West of England, West Yorkshire). Participants: Patients aged ≥ 18 years meeting Rome IV criteria for irritable bowel syndrome with ongoing symptoms after trying first-line treatments and no contraindications to TCAs. Intervention: Amitriptyline 10 mg once-daily, self-titrated by participants to a maximum of 30 mg once-daily or matched placebo for 6 months. Participants randomised 1 : 1 with most having the option to continue blinded treatment for a further 6 months. Main outcome measures: The primary participant-reported outcome was the effect of amitriptyline on global irritable bowel syndrome symptoms at 6 months, measured using the irritable bowel syndrome Severity Scoring System, with a 35-point between-group difference defined as the minimum clinically important difference. The key secondary outcome was the proportion of participants reporting subjective global assessment of relief at 6 months, defined as somewhat, considerable, or complete relief of symptoms. Other secondary outcomes included: effect on global symptoms, via the irritable bowel syndrome Severity Scoring System, and subjective global assessment of relief of irritable bowel syndrome symptoms at 3 and 12 months; effect on somatic symptom-reporting at 6 months; anxiety an–d depression scores; ability to work and participate in other activities at 3, 6 and 12 months; acceptability, tolerability and adherence to trial medication. Results: Four hundred and sixty-three participants were randomised to amitriptyline (232) or placebo (231). An intention-to-treat analysis of the primary outcome showed a significant difference in favour of amitriptyline for irritable bowel syndrome Severity Scoring System score between arms at 6 months [−27.0, 95% confidence interval (CI) −46.9 to −7.10; p = 0.008]. For the key secondary outcome of subjective global assessment of relief of irritable bowel syndrome symptoms, amitriptyline was superior to placebo at 6 months (odds ratio 1.78, 95% CI 1.19 to 2.66; p = 0.005). Amitriptyline was superior to placebo across a range of other irritable bowel syndrome symptom measures but had no impact on somatoform symptom-reporting, anxiety, depression, or work and social adjustment scores. Adverse event trial withdrawals were more common with amitriptyline (12.9% vs. 8.7% for placebo) but most adverse events were mild. The qualitative study thematically analysed 77 semistructured interviews with 42 participants and 16 GPs. Most participants found the self-titration process acceptable and empowering. Conclusions: General practitioners should offer low-dose amitriptyline to patients with irritable bowel syndrome whose symptoms do not improve with first-line therapies. Guidance and resources should support GP–patient communication to distinguish amitriptyline for irritable bowel syndrome from use as an antidepressant and to support patients managing their own dose titration. Study registration: This trial is registered as ISRCTN48075063. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 16/162/01) and is published in full in Health Technology Assessment Vol. 28, No. 66. See the NIHR Funding and Awards website for further award information.

11 March 2025 in Journal of Cell Biology
Verified
Journal Article
Open access
GTGabrielle L. Turvey
Gabrielle L. Turvey
EAErnesto López de Alba
Ernesto López de Alba
ESEmma Stewart
Emma Stewart
HCHeather Cook
Heather Cook
AAAhmad Alalti
Ahmad Alalti
DCDawn Coverley
Dawn Coverley
CIZ1 is part of the RNA-dependent supramolecular assemblies that form around the inactive X-chromosome (Xi) in female cells and smaller assemblies throughout the nucleus in both sexes. Here, we show that CIZ1 C-terminal anchor domain (AD) is elevated in human breast tumor transcriptomes, even at stage I. Elevation correlates with deprotection of chromatin and upregulation of lncRNA-containing gene clusters in ∼10 Mb regions enriched in cancer-associated genes. We modeled the effect of AD on endogenous CIZ1–Xi assemblies and observed dominant-negative interference with their reformation after mitosis, leading to abnormal assemblies similar to those in breast cancer cells, and depletion of H2AK119ub1, H3K27me3, and Xist. Consistent alterations in gene expression were evident across the genome, showing that AD-mediated interference has a destabilizing effect, likely by unscheduled exposure of underlying chromatin to modifying enzymes. The data argue for a dominant, potent, and rapid effect of CIZ1 AD that can deprogram gene expression patterns and which may predispose incipient tumors to epigenetic instability.

26 December 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
SWSteven Walker
Steven Walker
ETEllie Taylor
Ellie Taylor
AMAmy McAndrew
Amy McAndrew
ECEdward Carlton
Edward Carlton
ECElla Chaudhuri
Ella Chaudhuri
NMNick Maskell
Nick Maskell
Introduction Secondary spontaneous pneumothorax (SSP) is a medical emergency where the lung collapses in the presence of underlying chronic lung disease. Current international clinical guidelines advise intercostal drain (ICD) insertion for SSP. However, in a previous small study needle aspiration (NA) has been shown to reduce length of hospital stay (LOHS) and reduce complications. We are evaluating the clinical and cost-effectiveness of an initial NA approach to the management of patients with SSP in the United Kingdom. Methods and analysis The PRINCE-SSP (Pragmatic non-inferiority Randomised trial Investigating Needle aspiration vs ChEst drain for Secondary Spontaneous Pneumothorax) trial is a pragmatic, multicentre, open-label, parallel, two-group, randomised, non-inferiority trial to establish whether NA for SSP is non-inferior in terms of LOHS compared with ICD. We aim to recruit 110 patients from at least 15 UK NHS hospitals, over 18 months. Participants allocated to the intervention (NA) group will have an NA inserted at the presentation. Those allocated to the comparator (usual care) group will have an ICD inserted. Participants are followed up for 30 days. The primary outcome measure is initial LOHS, up to day 30 postrandomisation. Secondary outcomes include (but are not limited to) total LOHS including readmissions, complications, cost-effectiveness and patient-reported quality of life. Ethics and dissemination This trial received Health Research Authority (HRA) approval from Wales Research Ethics Committee seven ethics committee (23/WA/0085). Results will be submitted for publication in a peer-reviewed journal. A plain English summary of the trial results will be prepared and disseminated with the help of our patient advisory group, including via social media, and provided to trial participants via post or email according to their preference. Trial registration number ISRCTN12644940.

22 September 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
GTGabrielle L. Turvey
Gabrielle L. Turvey
EAErnesto López de Alba
Ernesto López de Alba
ESEmma Stewart
Emma Stewart
LBLewis Byrom
Lewis Byrom
HCHeather Cook
Heather Cook
DCDawn Coverley
Dawn Coverley
CIZ1 is a nuclear matrix protein that is part of the large RNA-dependent supramolecular assembly complexes (SMACs) that form at the inactive X chromosome (Xi) in female cells, and smaller assemblies throughout the nucleus in males and females. It plays a role in maintenance of epigenetic state and gene expression in differentiated cells, via stabilisation of histone post-translational modifications H2AK119ub1 and H3K27me3, added by polycomb repressive complexes (PRC) 1 and 2. Here, we show that expression of the N-terminal replication domain (RD) and C-terminal anchor domain (AD) of human CIZ1 transcript is uncoupled, with consistently elevated AD in early stage breast cancers, and sporadically elevated AD in other common solid tumours. At the protein level CIZ1-Xi SMACs are corrupted in female breast cancers cells, and this is accompanied by elevated AD-encoding transcripts. We modelled the effect of AD fragments in primary murine embryonic fibroblasts and observed dominant-negative interference with CIZ1 SMACs during their assembly in early G1 phase. Mutagenesis identified the matrin 3 homology domain as essential for self-interaction to form stable homodimers in vitro , and as a determinant of its dominant-negative effect in cells, implicating the dimerization interface in CIZ1 SMAC integrity. SMAC disruption was coincident with depletion of PRC1-dependent H2AK119ub1 from Xi chromatin, in a manner abrogated by the PR-deubiquitinase inhibitor PR619, suggesting that CIZ1 SMACs normally stabilise H2AK119ub1 by shielding Xi chromatin from attack by deubiquitinases. Moreover, SMAC disruption was accompanied by changes in gene expression within days. Together, the data suggest that inappropriate expression of CIZ1 AD fragments could drive epigenetic instability in early stage breast cancers by destabilizing the CIZ1 SMACs that normally protect repressed chromatin. Abstract Figure:

16 November 2023
Verified
Conference Paper
Open access
PDF file
HEHazel Everitt
Hazel Everitt
RFRobbie Foy
Robbie Foy
MRMatthew Ridd
Matthew Ridd
SASarah Alderson
Sarah Alderson
RTRuth Thornton
Ruth Thornton
POPei Loo Ow
Pei Loo Ow
Context: Most patients with irritable bowel syndrome (IBS) are managed in primary care. If first-line therapies are ineffective, UK NICE Guidelines suggests considering low dose tricyclic antidepressants (TCAs), but effectiveness in primary care is unknown and TCA are infrequently prescribed for IBS in this setting. Objective: To determine the clinical effectiveness of low dose amitriptyline (10-30mg) for adults with IBS in primary care. Study Design and Analysis: Randomised, double-blind, placebo-controlled trial. Participants, clinicians, investigators, and analysts masked to allocation. Intention to treat analyses for effectiveness, according to treatment receipt for safety analyses. Trial Registration ISRCTN48075063. Setting: 55 UK primary care centres. Population Studied: Adults ≥18 years with Rome IV IBS of any subtype, with ongoing symptoms despite first-line therapies, a normal full blood count and C-reactive protein, negative coeliac serology, and no evidence of suicidal ideation. Intervention: Participants randomised (1:1) to 6 months low-dose oral amitriptyline (10-30mg once daily) or identical placebo, participant self-titration according to symptoms and tolerability. Outcome Measures: Primary and key secondary endpoint: IBS-SSS score and Subjective Global Assessment (SGA) of relief of IBS symptoms at 6 months. Results: 463 patients (mean age 48.5 yrs (SD 16.1 yrs), 315 (68.0%) female) randomised, December 2019 to April 2022, to amitriptyline (232) or placebo (231). Primary outcome analysis showed a significant difference in IBS-SSS score at 6 months (−27.0; 95% CI −46.9 to −7.10, p=0.008) in favour of amitriptyline. For SGA of relief of IBS symptoms, amitriptyline was superior to placebo at 6 months (125/204 (61.3%) vs. 88/195 (45.1%), OR 1.78; 95% CI 1.19 to 2.66, p=0.005). Amitriptyline was superior to placebo across other secondary endpoints but had no impact on anxiety or depression. 46 (19.8%) patients discontinued amitriptyline (30 (12.9%) due to adverse events) and 59 placebo (25.5%) (20 (8.7%) adverse events). 5 serious adverse reactions (2 amitriptyline, 5 placebo) and 5 serious adverse events were unrelated to trial medication. Conclusions: This is the largest trial of a TCA in IBS ever conducted. Titrated low-dose amitriptyline was superior to placebo for IBS across multiple endpoints and safe. Primary care physicians should offer low-dose amitriptyline to patients with IBS whose symptoms do not improve with first-line therapies.

28 August 2025 in medRxiv
Verified
Preprint
Open access
PDF file
KJKatherine Joyce
Katherine Joyce
RLRebecca Lear
Rebecca Lear
FHFergus Hamilton
Fergus Hamilton
DADavid Arnold
David Arnold
ECElla Chaudhuri
Ella Chaudhuri
CACarlton
Carlton
Introduction: Cellulitis is a common bacterial skin infection causing significant pain, swelling, and impact on daily activities, frequently leading to emergency department presentations and hospital admissions. While antibiotics are the mainstay of treatment, they do not directly address inflammation, often resulting in persisting or worsening symptoms in the initial days. Corticosteroids, with their potent anti-inflammatory effects, have shown benefit in other acute infections but are not currently standard care for patients with cellulitis. This trial aims to determine if adjunctive oral dexamethasone can reduce pain and improve outcomes in adults with cellulitis presenting to UK urgent secondary care settings. Methods and analysis: This is a pragmatic, multicentre, double-blind, placebo-controlled, randomised, parallel group, phase 3 superiority trial, with an internal pilot and parallel health economic evaluation. Adult patients (≥16 years) with a clinical diagnosis of cellulitis (at any body site except the orbit) presenting to urgent secondary care will be screened for eligibility. 450 participants will be randomised (1:1) to receive either two 8 mg doses of oral dexamethasone or matched placebo, administered approximately 24 hours apart, in addition to standard antibiotic therapy. The primary outcome is total pain experienced over the first 3 days post-randomisation, calculated using the standardised area under the curve (AUC) from pain scores (Numerical Rating Scale 0-10) across up to seven timepoints. Secondary outcomes include health-related quality of life (EQ-5D-5L), patient global impression of improvement, analgesia and antibiotic usage, hospital (re)admissions, complications, unscheduled healthcare use, cellulitis recurrence, and cost-effectiveness at 90 days. The primary estimand will apply a treatment policy approach to intercurrent events. Ethics and dissemination: The trial has received ethical approval from South Central – Oxford B Research Ethics Committee (reference; 24/SC/0289) and will be conducted in compliance with GCP and applicable regulations. Informed consent will be obtained from all participants. Findings will be disseminated through peer-reviewed publications and conference presentations, and to patient groups and relevant clinical guideline committees. Trial registration: ISRCTN76873478. Current protocol version 5.0, 7th January 2025. Strengths and limitations of this study: This trial employs a robust double-blind, placebo-controlled design to minimise bias in assessing a subjective primary outcome (patient-reported pain). The pragmatic nature of the trial, recruiting from diverse urgent secondary care settings, with additional incentives to recruit from minoritised groups, aims to enhance the generalisability of findings to real-world clinical practice. Comprehensive follow-up to 90 days allows for assessment of both short-term symptom relief and longer-term impacts on healthcare utilisation and recurrence. The inclusion of a parallel health economic evaluation will provide crucial information on the cost-effectiveness of adjunctive dexamethasone. Potential variability in’usual care’ antibiotic regimens across sites, while reflecting real-world practice, is a possible limitation, which is accounted for in the pragmatic design.